Dual melanocortin‐4 receptor and GLP‐1 receptor agonism amplifies metabolic benefits in diet‐induced obese mice
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
We assessed the efficacy of simultaneous agonism at the glucagon‐like peptide‐1 receptor (GLP‐1R) and the melanocortin‐4 receptor (MC4R) for the treatment of obesity and diabetes in rodents. Diet‐induced obese (DIO) mice were chronically treated with either the long‐acting GLP‐1R agonist liraglutide, the MC4R agonist RM‐493 or a combination of RM‐493 and liraglutide. Co‐treatment of DIO mice with RM‐493 and liraglutide improves body weight loss and enhances glycemic control and cholesterol metabolism beyond what can be achieved with either mono‐therapy. The superior metabolic efficacy of this combination therapy is attributed to the anorectic and glycemic actions of both drugs, along with the ability of RM‐493 to increase energy expenditure. Interestingly, compared to mice treated with liraglutide alone, hypothalamic Glp‐1r expression was higher in mice treated with the combination therapy after both acute and chronic treatment. Further, RM‐493 enhanced hypothalamic Mc4r expression. Hence, co‐dosing with MC4R and GLP‐1R agonists increases expression of each receptor, indicative of minimized receptor desensitization. Together, these findings suggest potential opportunities for employing combination treatments that comprise parallel MC4R and GLP‐1R agonism for the treatment of obesity and diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 receptor agonists predominantly target non-MC4R-dependent neural pathways in mice19”
From Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency (2025) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189 · cited 1×
“Hepatic lipids were extracted as described previously (Folch et al , 1957), and cholesterol content was quantified using a commercially available kit (Thermo Scientific, Middletown, VA).”
Kopelman, P. G. (2000) · Nature · doi:10.1038/35007508 · Cited by 4,795 · cited 1×
“The etiology of metabolic disease is complex, with diverse pathophysiological mechanisms, emphasizing the challenges inherent in the development of medicinal options for the disorder (Kopelman, 2000; Scheen & Van Gaal, 2014).”
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“Glucagon-like peptide-1 receptor (GLP-1R) agonists represent the best-in-class pharmacotherapies for treating type 2 diabetes (Drucker & Nauck, 2006).”
Targeted disruption of the melanocortin-4 receptor results in obesity in mice
Huszar, D., Lynch, C. A., Fairchild-Huntress, V., Dunmore, J. H., Fang, Q., Berkemeier, L. R., Gu, W., Kesterson, R. A., Boston, B. A., Cone, R. D., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)81865-6 · Cited by 3,030 · cited 1×
“These observations and the finding that a plethora of MC4R loss-of-function variants predispose to human obesity have made the MC4R an attractive target for the development of novel, anti-obesity pharmacotherapies (Huszar et al , 1997; Yeo et al , 1998; Farooqi et al , 2003).”
Health and economic burden of the projected obesity trends in the USA and the UK
Wang, Y. C., McPherson, K., Marsh, T., Gortmaker, S. L., & Brown, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60814-3 · Cited by 2,692
Clinical Spectrum of Obesity and Mutations in the Melanocortin 4 Receptor Gene
Farooqi, I. S., Keogh, J. M., Yeo, G. S. H., Lank, E. J., Cheetham, T., & O'Rahilly, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022050 · Cited by 1,778
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · cited 1×
“Emerging evidence supports that GLP-1R agonism can lower body weight in obese subjects (Astrup et al , 2009; Madsbad, 2014), corroborating rodent studies.”
A frameshift mutation in MC4R associated with dominantly inherited human obesity
Yeo, G. S. H., Farooqi, I. S., Aminian, S., Halsall, D. J., Stanhope, R. G., & O'Rahilly, S. (1998) · Nature Genetics · doi:10.1038/2404 · Cited by 1,159
Divergence of Melanocortin Pathways in the Control of Food Intake and Energy Expenditure
Balthasar, N., Dalgaard, L. T., Lee, C. E., Yu, J., Funahashi, H., Williams, T., Ferreira, M., Tang, V., McGovern, R. A., Kenny, C. D., et al. (2005) · Cell · doi:10.1016/j.cell.2005.08.035 · Cited by 1,120
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“Several studies in mice [465,467,685,774] and humans [783e787] have failed to detect changes in energy expenditure following chronic or acute peripheral treatment with different GLP-1R agonists.”
BackgroundSelf-citationAnti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Self-citationThe Hunger Genes: Pathways to Obesity
van der Klaauw, A. A., & Farooqi, I. S. (2015) · Cell · doi:10.1016/j.cell.2015.03.008 · Cited by 393
“to be directed at highly specific targets and may consist of combinations of compounds that target different mechanisms, as illustrated by recent studies demonstrating the efficacy of dual melanocortin-4 receptor and GLP-1 receptor agonism (Clemmensen et al., 2015).”
Progress and challenges in anti-obesity pharmacotherapy
Bessesen, D. H., & Van Gaal, L. F. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30236-x · Cited by 347
Gut-Brain Cross-Talk in Metabolic Control
Clemmensen, C., Müller, T. D., Woods, S. C., Berthoud, H.-R., Seeley, R. J., & Tschöp, M. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.025 · Cited by 297
“…anorectic and thermogenic pathways is a superior medicinal strategy, dual MC4R and GLP-1R agonism administered to HFD-induced obese mice caused a greater improvement in reversing obesity and dyslipidemia as well as restoring glycemic control relative to each mono-agonist (Clemmensen et al., 2015).”
BackgroundSelf-citation
Metadata
- Authors
- Clemmensen, C., Finan, B., Fischer, K., Tom, R. Z., Legutko, B., Sehrer, L., Heine, D., Grassl, N., Meyer, C. W., Henderson, B., Hofmann, S. M., Tschöp, M. H., Van der Ploeg, L. H., & Müller, T. D.
- Affiliations
- Helmholtz Munich (DE)
- Rhythm (United states) (US)
- Corresponding author
- Müller, Timo D
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2015-02-04
- Volume
- 7
- Issue
- 3
- Pages
- 288-298
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC4364946
- OpenAlex
- W2128463942
- Cited by
- 89
- References
- 36
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 8 · 2023: 4 · 2022: 4 · 2021: 12 · 2020: 5 · 2019: 5 · 2018: 8 · 2017: 13 · 2016: 7 · 2015: 8
- FWCI
- 6.62
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Site cant be reached (submittedVersion, cc-by)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by)
- Funders
- Deutsche Forschungsgemeinschaft (DFG TS226/1‐1)
- Alfred Benzon Foundation
- Rhythm
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- melanocortin-4 receptor, GLP-1 receptor, combination therapy, liraglutide, diet-induced obesity, obesity, type 2 diabetes, glycemic control, cholesterol metabolism, energy expenditure, receptor desensitization, weight loss
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, alpha-MSH, Animals, Diabetes Mellitus, Drug Synergism, Drug Therapy, Combination, Hypoglycemic Agents, Mice, Obese, Obesity, Treatment Outcome, Receptors, Glucagon, Receptor, Melanocortin, Type 4, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dual melanocortin‐4 receptor and GLP‐1 receptor agonism amplifies metabolic benefits in diet‐induced obese mice. https://app.cochat.ai/papers/10.15252/emmm.201404508
- The paper
- Clemmensen, C., Finan, B., Fischer, K., Tom, R. Z., Legutko, B., Sehrer, L., Heine, D., Grassl, N., Meyer, C. W., Henderson, B., Hofmann, S. M., Tschöp, M. H., Van der Ploeg, L. H., & Müller, T. D. (2015). Dual melanocortin‐4 receptor and GLP‐1 receptor agonism amplifies metabolic benefits in diet‐induced obese mice. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201404508
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.